Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Taxotere · 1 trial · 1 indication
Number of patients with/without recurrence of breast cancer, or death due to any cause.
Disease free survival was measured as the time from the date of randomization until the date of first event (recurrence of breast cancer, or death due to any cause). Patients without event at the time of the analysis were censored using the date they were last known to be recurrent disease free.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| capecitabine [Xeloda] | DRUG | 825mg/m2 po bid on days 1-14 of each 3 week cycle |
| Taxotere | DRUG | 75mg/m2 iv on day 1 of each 3 week cycle |
Inclusion Criteria: * female patients 18-70 years of age; * adenocarcinoma of the breast; * previous invasive breast cancer if diagnosed \>5 years before entering study; * no evidence of metastatic disease. Exclusion Criteria: * history of severe hypersensitivity reaction to Taxotere; * previous ...
Top 20 of 92 competitors
Taxotere is a small molecule oncology drug being studied for the treatment of breast cancer. It is currently in Phase 3 clinical development for this indication. The drug is being evaluated in women with high-risk breast cancer.
Taxotere is developed by Roche Holding AG, a company traded under the ticker RHHBY. Roche is conducting clinical trials to evaluate the drug's use in breast cancer treatment.
Taxotere is in Phase 3 clinical development for breast cancer. It is an investigational drug and has not been approved for this use. One Phase 3 trial has been completed to assess its effects in patients with high-risk breast cancer.
Taxotere has been studied in a completed Phase 3 clinical trial with the identifier NCT00089479. This trial enrolled 2,611 women with high-risk breast cancer and was conducted in the United States. The study was active-controlled, meaning patients received an alternative treatment for comparison.
Taxotere is not the same as capecitabine. In the clinical trial NCT00089479, Taxotere was evaluated in combination with capecitabine, which is also known as Xeloda. The study compared this combination against a control treatment in women with high-risk breast cancer.